drug
pralsetinib
Marketedupdated 3mo agoby Blueprint Medicines Corp
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2indications
investigational
NSCLC
all catalysts(0)
nothing on the calendar yet
Trials studying pralsetinib
- phase4Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors
- phase2Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- phase2A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
- phase3A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
- phase2Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
- —KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
- phase2A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
- phase3A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 4, 2027
~1.0 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Jul 7, 2042compositionUS 12448366
- Apr 3, 2039method-of-use (U-2952)US 11273160
- Apr 3, 2039method-of-use (U-2952)US 11872192
- Apr 3, 2039method-of-use (U-2828)US 11963958
- Apr 3, 2039method-of-use (U-2828)US 12539303
- Nov 1, 2036compositionUS 10030005
FDA exclusivities (3)
- Dec 1, 2027ODE-340Orphan Drug (7y)1.3y
- Dec 1, 2027ODE-341Orphan Drug (7y)1.3y
- Sep 4, 2027ODE-318Orphan Drug (7y)1.0y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that